Washington University

Eli Lilly and Company

David Michael Holtzman

Steven Marc Paul

Kelly R Bales

Ronald DeMattos

Hong Jiang

Maximiliano Vasquez

Naoya Tsurushita

Randall John Bateman

David J Cummins

Mark S Dennis

Yin Sheng Zhang

Ryan Jefferson Watts

Adam P Silverman

Thu Nga Bien-Ly

Jing Guo

Xianlin Han

Marc Diamond

Najla Kfoury

Brandon B Holmes

Chihiro Sato

Kwasi Mawuenyega

Anne Fagan Niven

Fan Liao

Tim Miller

Jason Ulrich

The present disclosure encompasses anti-TREM-2 antibodies that promote TREM-2 activation and methods of using the anti-TREM-2 agonist antibodies therapeutically.

Anti-TREM-2 agonist antibodies

The present disclosure encompasses compositions and methods for effectively treating at least one symptom or sign of Aß plaque or cerebral amyloid angiopathy (CAA) associated symptoms, or for decreasing amyloid plaque load or CAA load. The method comprises administering an effective amount of an anti-ApoE antibody to a mammalian subject, such as to a human.

Anti-ApoE antibodies

The present disclosure encompasses compositions and methods for effectively treating at least one symptom or sign of A plaque or cerebral amyloid angiopathy (CAA) associated symptoms, or for decreasing amyloid plaque load or CAA load. The method comprises administering an effective amount of an anti-ApoE antibody to a mammalian subject, such as to a human.

The invention relates to in vitro methods for measuring the in vivo metabolism of tau in a subject.

Tau kinetic measurements

This invention relates to antibodies to tau and methods of use thereof.

Antibodies to tau

A diagnostic test for preclinical and clinical Alzheimer's disease is based on plasma levels of A&#x3b2;, A&#x3b2;, their ratio, or their rate of entry following administration of antibodies that sequester A&#x3b2;. Alterations of any of these parameters from control values identifies preclinical or clinical Alzheimer's disease.

Assay method for Alzheimer's disease

A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A&#x3b2; peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide A&#x3b2;.

Humanized antibodies that sequester amyloid beta peptide

The present invention relates to methods of diagnosing, monitoring, and assessing treatment effects for neurological and neurodegenerative diseases and disorders, such as Alzheimer's Disease, early in the course of clinical disease or prior to the onset of brain damage and clinical symptoms. Methods of measuring the in vivo metabolism of biomolecules produced in the CNS in a subject are provided.

Methods for measuring the metabolism of neurally derived biomolecules in vivo

Methods for measuring the metabolism of neurally dervied biomolecules in vivo

Assay method for alzheimer's disease

A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A&#x3b2; peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13&#x2013;28 of the amyloid beta peptide A&#x3b2;.

Humanized antibodies that sequester abeta peptide

A method for diagnosing Alzheimer's disease even at early stages by assessing the levels of sulfatides or its metabolites in biological fluids is disclosed.

Diagnostic for early stage Alzheimer's disease

A diagnostic method for identifying individuals at risk for developing Alzheimer's disease is disclosed. The method relies on elevated levels of the ratio of A&bgr; /A&bgr; associated with lipoproteins in the cerebrospinal fluid of individuals at risk as compared to this ratio in the overall population.

Growing community of inventors

St. Louis, MO, United States of America

David Michael Holtzman